Zyvox Dosage

Generic name: linezolid
Dosage form: injection, tablets, oral suspension

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

General Dosage and Administration

The recommended dosage for ZYVOX formulations for the treatment of infections is described in Table 1.

Table 1. Dosage Guidelines for ZYVOX


Infection*
Dosage and Route of Administration Recommended Duration of Treatment (consecutive days)
Pediatric Patients (Birth through 11 Years of Age) Adults and Adolescents
(12 Years and Older)
*
Due to the designated pathogens [see Indications and Usage (1)]
Neonates <7 days: Most pre-term neonates <7 days of age (gestational age <34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg every 8 hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg every 8 hours by 7 days of life [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)].
Oral dosing using either ZYVOX Tablets or ZYVOX for Oral Suspension [see How Supplied/Storage and Handling (16)].
Nosocomial pneumonia 10 mg/kg intravenously or oral every 8 hours
600 mg intravenously or oral every 12 hours 10 to 14
Community-acquired pneumonia, including concurrent bacteremia      
Complicated skin and skin structure infections      
Vancomycin-resistant Enterococcus faecium infections, including concurrent bacteremia 10 mg/kg intravenously or oral every 8 hours
600 mg intravenously or oral every 12 hours 14 to 28
Uncomplicated skin and skin structure infections <5 yrs: 10 mg/kg oral every 8 hours
5–11 yrs: 10 mg/kg oral every
12 hours
Adults: 400 mg oral every
12 hours
Adolescents: 600 mg oral every 12 hours

10 to 14

No dose adjustment is necessary when switching from intravenous to oral administration.

Intravenous Administration

ZYVOX I.V. Injection is supplied in single-use, ready-to-use infusion bags. Parenteral drug products should be inspected visually for particulate matter prior to administration. Check for minute leaks by firmly squeezing the bag. If leaks are detected, discard the solution, as sterility may be impaired. Keep the infusion bags in the overwrap until ready to use. Store at room temperature. Protect from freezing. ZYVOX I.V. Injection may exhibit a yellow color that can intensify over time without adversely affecting potency.

ZYVOX I.V. Injection should be administered by intravenous infusion over a period of 30 to 120 minutes. Do not use this intravenous infusion bag in series connections. Additives should not be introduced into this solution. If ZYVOX I.V. Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each product.

If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of ZYVOX I.V. Injection with an infusion solution compatible with ZYVOX I.V. Injection and with any other drug(s) administered via this common line.

Compatibilities

Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, and Lactated Ringer's Injection, USP.

Incompatibilities

Physical incompatibilities resulted when ZYVOX I.V. Injection was combined with the following drugs during simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isothionate, erythromycin lactobionate, phenytoin sodium, and trimethoprim-sulfamethoxazole. Additionally, chemical incompatibility resulted when ZYVOX I.V. Injection was combined with ceftriaxone sodium.

Constitution of Oral Suspension

ZYVOX for Oral Suspension is supplied as a powder/granule for constitution. Gently tap bottle to loosen powder. Add a total of 123 mL distilled water in two portions. After adding the first half, shake vigorously to wet all of the powder. Then add the second half of the water and shake vigorously to obtain a uniform suspension. After constitution, each 5 mL of the suspension contains 100 mg of linezolid. Before using, gently mix by inverting the bottle 3 to 5 times. Do not shake. Store constituted suspension at room temperature. Use within 21 days after constitution.

Hide
(web3)